Clinical trials: Dosimetry
Neuroendocrine Tumors
Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs
The purpose of this clinical phase I/II study was to investigate the safety and tolerability of satoreotide tetraxetan (177Lu-IPN01072, formerly known as 177Lu-OPS201) used for the treatment of patients with neuroendocrine tumors…
- Trial name
- NCT02592707
- Testing
- Satoreotide tetraxetan, Amino acid solution, Antiemetic
- Where
- 9 sites in United States, Australia and 6 more
- Volunteers
- 40 people
- Sponsor
- Ipsen
Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
This is a multicenter, open-label, single-arm study to evaluate the safety and dosimetry of Lutathera in adolescent patients 12 to <18 years old with somatostatin receptor positive GEP-NETs and PPGLs.
- Conditions
- Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma
- Trial name
- NETTER-P (NCT04711135)
- Testing
- Lutetium [177Lu] oxodotreotide/dotatate
- Where
- 7 sites in United States, France and 3 more
- Volunteers
- 11 people
- Sponsor
- Advanced Accelerator Applications
Healthy Volunteers, Breast Cancer
Study to Evaluate the Safety, Biodistribution, Radiation Dosimetry and Tumor Imaging Potential of [131I]-SGMIB Anti-HER2 VHH1 in Healthy Volunteers and Breast Cancer Patients
Primary purpose of the clinical study is to evaluate the safety, biodistribution and radiation dosimetry of [131I]-SGMIB Anti-HER2 VHH1 in healthy volunteers and patients with HER2+ breast cancer.
- Trial name
- CAM-VHH1 (NCT02683083)
- Testing
- [131I]-SGMIB Anti-HER2 VHH1
- Where
- Belgium
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Precirix
Prostate Cancer, Prostatic Cancer
CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry
The purpose of this study is to investigate the effects of CyberKnife radiosurgery in patients with early stage organ-confined prostate cancer and to evaluate the effects of this treatment on the quality of life over time.
- Conditions
- Prostate Cancer, Prostatic Cancer, Prostatic Neoplasms, Prostate Neoplasms
- Trial name
- NCT00643617
- Testing
- CyberKnife Stereotactic Radiosurgery - Low Risk, CyberKnife Stereotactic Radiosurgery - Intermediate Risk
- Where
- 18 sites in United States
- Volunteers
- 307 people
- Sponsor
- Accuray Incorporated
Alzheimer's Disease
Safety, Radiation Dosimetry, Biokinetics, and Effectiveness of [18F]MK3328 (MK-3328-001)
This study will estimate the radiochemical and radiation safety and assess the efficacy of [18F]MK-3328, a novel positron emission tomography (PET) tracer.
- Trial name
- NCT00954538
- Testing
- [18F]MK-3328
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Pheochromocytoma, Paraganglioma
Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
The purpose of this study is to determine whether iobenguane I 131 is safe and effective in patients with malignant pheochromocytoma or paraganglioma.
- Trial name
- NCT00458952
- Testing
- Ultratrace Iobenguane (MIBG) I 131
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Molecular Insight Pharmaceuticals, Inc.
Lymphoma, Non-Hodgkin
Dosimetry/Validation Study of 131Iodine-Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas That Have Transformed to Higher Grade Histologies
Study RIT-II-001 is a phase II, multicenter study of the safety, tumor and organ dosimetry, dosimetry methods, and efficacy of Iodine-131 Anti-B1 Antibody for the treatment of patients with low-grade or transformed low-grade…
- Trial name
- RIT-II-001 (NCT01224821)
- Testing
- Tositumomab (Anti-B1 Antibody) and Iodine-131 Tositumomab
- Volunteers
- 47 people
- Sponsor
- GlaxoSmithKline
Metastatic Prostate Cancer, Castration-resistant Prostate Cancer
I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).
This clinical trial was done to show whether a radioactive drug (I-131-1095) that binds to prostate-specific membrane antigen (PSMA) is useful in treating metastatic prostate cancer that is positive for PSMA.
- Conditions
- Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Prostatic Neoplasm, Cancer of the Prostate
- Trial name
- ARROW (NCT03939689)
- Testing
- I-131-1095, Enzalutamide
- Where
- 27 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- Progenics Pharmaceuticals, Inc.
Prostate Cancer
A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer
The purpose of this study is to find the highest dose level of study drug, CTT1403, that can be safely administered to patients with metastatic castration resistant prostate cancer (mCRPC).
- Trial name
- NCT03822871
- Testing
- CTT1403, CTT1057, 68Ga-PSMA-11
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Cancer Targeted Technology
Healthy Subjects (HS)
A Study to Evaluate the Safety, Biodistribution, Internal Radiation Dosimetry, and Effective Dose of DaTSCAN™ Ioflupane (123I) Injection in Chinese Healthy Volunteers.
This is a phase 1, single-centre, single-group, nonrandomized, noncomparative, open-label, single-dose study to evaluate the safety, biodistribution, internal radiation dosimetry, and effective dose of DaTSCAN™ ioflupane (123I)…
- Trial name
- NCT04564092
- Testing
- DaTSCAN™ Ioflupane (123I) Injection
- Where
- China
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Prostate Cancer
Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate Cancer
A Phase 1, Open-label Study to Assess Safety, Biodistribution, and Internal Radiation Dosimetry of rhPSMA-7.3 (18F) Injection in Healthy Volunteers, and to Assess Safety and Investigate the Imaging Characteristics in Subjects…
- Trial name
- NCT03995888
- Testing
- rhPSMA-7.3 (18F) Injection
- Where
- Finland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Blue Earth Diagnostics
Alzheimer's Disease
Augmenting Flortaucipir Dosimetry Estimates
This study will obtain data from urine in subjects administered flortaucipir in an Avid-sponsored study to augment the calculation of radiation dosimetry estimates.
- Trial name
- NCT02336360
- Testing
- Flortaucipir F18
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Gastroenteropancreatic Neuroendocrine Tumors
68Ga-OPS202 Study for Diagnostic Imaging of GEP NET
The purpose of this study is to assess the safety and tolerability of 68Ga-OPS202 used for the diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP NETs).
- Trial name
- NCT02162446
- Testing
- satoreotide trizoxetan
- Where
- Switzerland
- Volunteers
- 12 people
- Sponsor
- Ipsen
Lymphoma, Follicular
A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma
Patients will receive a standard 5 mCi dosimetric dose of fission-derived Iodine I 131 Tositumomab. Pharmacokinetic data for the primary endpoint analysis will be derived from testing done on blood samples drawn at 12 timepoints…
- Trial name
- NCT00315731
- Testing
- Follicular Lymphoma
- Volunteers
- 15 people
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis, Ankylosing Spondylitis
99mTc-rhAnnexin V-128 a Phase I/IIa Study in Patients With Rheumatoid Arthritis (RA) or Ankylosing Spondylitis (AS)
This was a monocentric, open label, Phase I-IIa study. Eligible patients who signed the ICF received two single intravenous (IV) bolus of the imaging agent 99mTc-rhAnnexin V-128.
- Trial name
- NCT02328027
- Testing
- 99mTc-rhAnnexin V-128
- Where
- Switzerland
- Volunteers
- 16 people
- Sponsor
- Advanced Accelerator Applications
Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2 Standard of Care Treatment
A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer
This is a Phase 1/2 multi-center, open label, dose escalation and dose expansion study to evaluate safety, tolerability, dosimetry, pharmacodynamics (PD), and efficacy of the targeted radionuclide therapeutic CAM-H2 in patients…
- Trial name
- NCT04467515
- Testing
- CAM-H2
- Where
- 12 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- Precirix